Irofulven

Irofulven

Chemical structure of Irofulven

Irofulven is a chemotherapy agent derived from the natural product illudin S, which is found in the Jack O'Lantern mushroom (Omphalotus illudens). It is a member of the acyclic sesquiterpene family and has been studied for its potential use in the treatment of various cancers.

Mechanism of Action

Irofulven exerts its antitumor effects by inducing DNA damage in cancer cells. It forms covalent bonds with DNA, leading to DNA strand breaks and apoptosis. Unlike many other alkylating agents, irofulven requires metabolic activation by NADPH-dependent aldo-keto reductases to become active. This unique mechanism allows it to target tumor cells selectively, as these cells often have higher levels of these enzymes.

Clinical Development

Irofulven has been evaluated in several clinical trials for its efficacy against different types of cancer, including prostate cancer, ovarian cancer, and pancreatic cancer. Although it showed promise in early-phase trials, its development has been challenging due to its toxicity profile and the emergence of more effective treatments.

Side Effects

The administration of irofulven can lead to several side effects, which are common with many chemotherapy agents. These include:

• Myelosuppression
• Nausea and vomiting
• Fatigue
• Liver enzyme elevation

Due to these side effects, careful monitoring of patients is necessary during treatment.

Future Directions

Research is ongoing to improve the therapeutic index of irofulven. Strategies include the development of prodrugs and combination therapy with other agents to enhance its efficacy and reduce toxicity. Additionally, identifying biomarkers that predict response to irofulven could help tailor treatments to patients most likely to benefit.

Related Pages

• Chemotherapy
• DNA damage
• Cancer treatment
• Alkylating agents